To meet the demand for innovative treatments based on cell therapy, it’s essential that Johnson&Johnson delivers solutions that are both faster and more cost-effective. Optimizing lentiviral vector (LVV) design and production is critical for advancing a subset of these therapies like CAR-T.

The primary challenge lies in developing scalable production systems that achieve high viral titers while ensuring the purity and stability of viral vectors to preserve safety and efficacy. Moreover, compliance with stringent regulatory requirements is paramount.

In this symposium, Johnson&Johnson addresses  key questions facing the biotech industry today: What are some of the main challenges in improving cutting-edge manufacturing techniques? How can Johnson&Johnsonboost LVV yield and enhance safety profiles? What insights can we gain from viral vector production applied in other areas like vaccines and gene therapy? Watch the webinar here.